Search

Apoptosis associated speck like protein containing a card (ASC), the key adaptor protein of the assembly and activation of canonical inflammasomes, has been found to play a significant role in neuroinflammation after spinal cord injury (SCI). The previous studies indicated that widely block or knockout ASC can ameliorate SCI. However, ASC is ubiquitously expressed in infiltrated macrophages and local microglia, so further exploration is needed on which type of cell playing the key role. In this study, using the LysMcre;Ascflox/flox mice with macrophage-specifc ASC conditional knockout (CKO) and contusive SCI model, we focus on evaluating the specific role of ASC in lysozyme 2 (LysM)+ myeloid cells (mainly infiltrated macrophages) in this pathology. The results revealed that macrophage-specifc Asc CKO exhibited the follow effects: (1) A significant reduction in the numbers of infiltrated macrophages in the all phases of SCI, and activated microglia in the acute and subacute phases. (2) A significant reduction in ASC, caspase-1, interleukin (IL)-1β, and IL-18 compared to control mice. (3) In the acute and subacute phases of SCI, M1 subset differentiation was inhibited, and M2 differentiation was increased. (4) Histology and hindlimb motor recoveries were improved. In conclusion, this study elucidates that macrophage-specific ASC CKO can improve nerve function recovery after SCI by regulating M1/M2 polarization through inhibiting ASC-dependent inflammasome signaling axis. This indicates that ASC in peripheral infiltrated macrophages may play an important role in SCI pathology, at least in mice, could be a potential target for treatment. [Display omitted] • Asc CKO can reduce the infiltration of macrophages after SCI in mice. • Asc CKO can reduce the activated microglia in the acute and subacute phases of SCI. • Asc CKO can inhibit ASC-dependent inflammasome signaling axis. • Asc CKO can inhibit M1 polarization, and increase M2 polarization. • Asc CKO can improve histology and hindlimb motor recoveries after SCI. [ABSTRACT FROM AUTHOR]

Full-scale fatigue test is an effective method for validating the fatigue performance of wind turbine blade. Its primary problem is how to design the test load. The conventional approach to determine test load requires a complicated and time-consuming process. Thus, a simplified method for directly converting load spectrum of blade into test load is proposed in this paper. Firstly, beam theory is used to obtain the relationship between stress, strain and bending moment of blade cross section. Based on the assumption of local stress concentration and linear relationship between stress and strain, M-N curves (applied moment vs. allowable number of cycles to failure) is defined. Secondly, based on Miner's linear cumulative damage theory and constant life diagram, the equivalent fatigue cumulative damage of load spectrum which is equal to the damage of full-scale fatigue test is obtained. Then, in the case of the selected test load ratio and cycles, the mean and amplitude of test load can be solved. Finally, the validity of the proposed method is verified by an illustrative example. The result indicates that the error of the calculated results between this method and the traditional method is close to 5 %, and it can be used for fatigue test and improve the efficiency of test load design. [ABSTRACT FROM AUTHOR]

Inflammation is one of the key injury factors for spinal cord injury (SCI). Exosomes (Exos) derived from M2 macrophages have been shown to inhibit inflammation and be beneficial in SCI animal models. However, lacking targetability restricts their application prospects. Considering that chemokine receptors increase dramatically after SCI, viral macrophage inflammatory protein II (vMIP-II) is a broad-spectrum chemokine receptor binding peptide, and lysosomal associated membrane protein 2b (Lamp2b) is the key membrane component of Exos, we speculated that vMIP-II-Lamp2b gene-modified M2 macrophage-derived Exos (vMIP-II-Lamp2b-M2-Exo) not only have anti-inflammatory properties, but also can target the injured area by vMIP-II. In this study, using a murine contusive SCI model, we revealed that vMIP-II-Lamp2b-M2-Exo could target the chemokine receptors which highly expressed in the injured spinal cords, inhibit some key chemokine receptor signaling pathways (such as MAPK and Akt), further inhibit proinflammatory factors (such as IL-1β, IL-6, IL-17, IL-18, TNF-α, and iNOS), and promote anti-inflammatory factors (such as IL-4 and Arg1) productions, and the transformation of microglia/macrophages from M1 into M2. Moreover, the improved histological and functional recoveries were also found. Collectively, our results suggest that vMIP-II-Lamp2b-M2-Exo may provide neuroprotection by targeting the injured spinal cord, inhibiting some chemokine signals, reducing proinflammatory factor production and modulating microglia/macrophage polarization. [Display omitted] • vMIP-II-Lamp2b-M2-Exo can target the injured spinal cord by vMIP-II. • vMIP-II-Lamp2b-M2-Exo can inhibit MAPK and AKT signaling pathways. • vMIP-II-Lamp2b-M2-Exo can reduce proinflammatory factor production. • vMIP-II-Lamp2b-M2-Exo can inhibit M1 microglia/macrophage polarization. • The early administration of vMIP-II-Lamp2b-M2-Exo is a promising strategy for SCI. [ABSTRACT FROM AUTHOR]